166 related articles for article (PubMed ID: 9711219)
1. Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci.
Rodriguez MJ; Snyder NJ; Zweifel MJ; Wilkie SC; Stack DR; Cooper RD; Nicas TI; Mullen DL; Butler TF; Thompson RC
J Antibiot (Tokyo); 1998 Jun; 51(6):560-9. PubMed ID: 9711219
[TBL] [Abstract][Full Text] [Related]
2. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Zweifel MJ; Wilkie SC; Rodriguez MJ; Thompson RC; Cooper RD
Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
[TBL] [Abstract][Full Text] [Related]
3. Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity.
Cooper RD; Snyder NJ; Zweifel MJ; Staszak MA; Wilkie SC; Nicas TI; Mullen DL; Butler TF; Rodriguez MJ; Huff BE; Thompson RC
J Antibiot (Tokyo); 1996 Jun; 49(6):575-81. PubMed ID: 8698642
[TBL] [Abstract][Full Text] [Related]
4. Glycopeptide carboxamides active against vancomycin-resistant enterococci.
Zweifel MJ; Snyder NJ; Cooper RD; Nicas TI; Mullen DL; Butler TF; Rodriguez MJ
J Antibiot (Tokyo); 2003 Mar; 56(3):289-95. PubMed ID: 12760685
[TBL] [Abstract][Full Text] [Related]
5. Novel semi-synthetic glycopeptide antibiotics active against methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): doubly-modified water-soluble derivatives of chloroorienticin B.
Yoshida O; Yasukata T; Sumino Y; Munekage T; Narukawa Y; Nishitani Y
Bioorg Med Chem Lett; 2002 Nov; 12(21):3027-31. PubMed ID: 12372494
[TBL] [Abstract][Full Text] [Related]
6. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
[TBL] [Abstract][Full Text] [Related]
7. [Chemical modification of glycopeptide antibiotics].
Pavlov AIu; Preobrazhenskaia MN
Bioorg Khim; 1998 Sep; 24(9):644-62. PubMed ID: 9813730
[TBL] [Abstract][Full Text] [Related]
8. Comparison of LY264826-gentamicin with vancomycin-gentamicin against enterococci from blood cultures.
Watanakunakorn C
J Antimicrob Chemother; 1992 Mar; 29(3):303-6. PubMed ID: 1592699
[TBL] [Abstract][Full Text] [Related]
9. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of the new glycopeptide LY264826 versus vancomycin against clinical isolates of enterococci.
Watanakunakorn C
Eur J Clin Microbiol Infect Dis; 1991 Nov; 10(11):982-3. PubMed ID: 1794373
[No Abstract] [Full Text] [Related]
11. N'-(alpha-aminoacyl)- and N'-alpha-(N-alkylamino)acyl derivatives of vancomycin and eremomycin. II. Antibacterial activity of N'-(alpha-aminoacyl)- and N'-alpha-(N-alkylamino)acyl derivatives of vancomycin and eremomycin.
Plattner JJ; Chu D; Mirchink EP; Isakova EB; Preobrazhenskaya MN; Olsufyeva EN; Miroshnikova OV; Printsevskaya SS
J Antibiot (Tokyo); 2007 Apr; 60(4):245-50. PubMed ID: 17456974
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of LY264826 compared to other glycopeptides and daptomycin.
Chin NX; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(2):181-4. PubMed ID: 1651826
[TBL] [Abstract][Full Text] [Related]
13. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.
Malabarba A; Ciabatti R; Scotti R; Goldstein BP; Ferrari P; Kurz M; Andreini BP; Denaro M
J Antibiot (Tokyo); 1995 Aug; 48(8):869-83. PubMed ID: 7592033
[TBL] [Abstract][Full Text] [Related]
14. Self-assembled multivalent vancomycin on cell surfaces against vancomycin-resistant enterococci (VRE).
Xing B; Ho PL; Yu CW; Chow KH; Gu H; Xu B
Chem Commun (Camb); 2003 Sep; (17):2224-5. PubMed ID: 13678212
[TBL] [Abstract][Full Text] [Related]
15. Importance of the structure of vancomycin binding pocket in designing compounds active against vancomycin-resistant enterococci (VRE).
Jia Y; Bois-Choussy M; Malabarba A; Brunati C; Zhu J
J Antibiot (Tokyo); 2006 Sep; 59(9):543-52. PubMed ID: 17136887
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of hydrophobic N'-mono and N',N"-double alkylated eremomycins inhibiting the transglycosylation stage of bacterial cell wall biosynthesis.
Pavlov AY; Miroshnikova OV; Printsevskaya SS; Olsufyeva EN; Preobrazhenskaya MN; Goldman RC; Branstrom AA; Baizman ER; Longley CB
J Antibiot (Tokyo); 2001 May; 54(5):455-9. PubMed ID: 11480890
[TBL] [Abstract][Full Text] [Related]
17. [Non-natural aglycones of glycopeptide antibiotics of the vancomycin group. Synthesis and antibacterial activity].
Pavlov AIu; Olsuf'eva EN; Miroshnikova OV; Reznikova MI; Lazhko EI; Malabarba A; Ciabatti R; Preobrazhenskaia MN
Bioorg Khim; 1997 May; 23(5):410-21. PubMed ID: 9290051
[TBL] [Abstract][Full Text] [Related]
18. Lipophilic teicoplanin pseudoaglycon derivatives are active against vancomycin- and teicoplanin-resistant enterococci.
Szűcs Z; Bereczki I; Csávás M; Rőth E; Borbás A; Batta G; Ostorházi E; Szatmári R; Herczegh P
J Antibiot (Tokyo); 2017 May; 70(5):664-670. PubMed ID: 28144040
[TBL] [Abstract][Full Text] [Related]
19. Enzymatic deacylation of teicoplanin followed by reductive alkylation: synthesis and antibacterial activity of new glycopeptides.
Snyder NJ; Cooper RD; Briggs BS; Zmijewski M; Mullen DL; Kaiser RE; Nicas TI
J Antibiot (Tokyo); 1998 Oct; 51(10):945-51. PubMed ID: 9917008
[TBL] [Abstract][Full Text] [Related]
20. The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant Enterococci.
Arnusch CJ; Bonvin AM; Verel AM; Jansen WT; Liskamp RM; de Kruijff B; Pieters RJ; Breukink E
Biochemistry; 2008 Dec; 47(48):12661-3. PubMed ID: 18989934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
